Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population. Database Analysis of Previous Studies Performed in Spain

Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00998062

Acronym

DARIOS

Enrollment

30181

Registered

2009-10-20

Start date

2009-11-30

Completion date

2011-10-31

Last updated

2011-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis Risk, Dyslipaemia, Increased hsCRP, Inflammatory and Oxidative Status in the Spanish Population

Keywords

Dyslipaemia, atherosclerosis risk, increased hsCRP, inflammatory and oxidative status in the Spanish population

Brief summary

The present project is aimed at determining the prevalence of LDL-C \<130 mg/dl with hsCRP ≥2mg/l, and of HDL-C \< 40 mg/dl in Spain together with the estimation of cardiovascular risk, to analyze the contribution of measuring hsCRP for primary prevention purposes. In a subgroup of that population a number of inflammatory and oxidative status biomarkers would be also measured to better understand the meaning of elevated hsCRP.The study aim to analyze data already collected in studies (11 studies will participate) carried out in Spain, in 10 Spanish regions, after the year 2000.

Interventions

None listed

Study design

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

35 Years to 74 Years

Healthy volunteers

Inclusion criteria

* Have an Informed consent form signed when the patient accepted to participate in the study already performed. * Spanish population between * Data from Epidemiological studies performed after the year 2000

Exclusion criteria

* Spanish population outside the age range * Data from Epidemiological studies performed before the year 2000

Design outcomes

Primary

Measure	Time frame
Lipid fractions: high-density lipoprotein, low-density lipoprotein, and total cholesterol, and triglycerides, and dislipidemia treatments	retrospectively

Secondary

Measure	Time frame
High sensitivity C reactive protein & CHR risk by Framingham adapted functions	retrospectively
Lipid profile among the Spanish regions, as in the primary outcome variable	retrospectively
Biomarkers: Interleukines 6 and 10, oxidized LDL, VCAM, ICAM, TNF alpha, neopterin, fibrinogen, lp(a), MMP 9 Apo A, Apo B, adiponectin, leptin, resistin, and yet other	prospectively

Countries

Spain

Outcome results